Mithra Pharmaceuticals S.A. — Major Shareholding Notification 2018

Jul 4, 2018

{0}------------------------------------------------

PUBLICATION OF A TRANSPARENCY NOTIFICATION RECEIVED FROM MEUSINVEST SA

Liège, Belgium, 04 July 2018, 18:00 CEST - Regulated Information – Mithra Pharmaceuticals SA/NV (Euronext Brussels: MITRA) today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of transparency from Meusinvest SA, having its registered seat located at 4000 Liège, Rue Lambert Lombart 3, on 02 July 2018.

Meusinvest has notified Mithra that it has dropped below the 15% threshold on June 4 2018, following the capital increase by means of a private placement launched on May 30 2018. Meusinvest now holds 14.37% (5,410,551 shares) of the 37,639,495 shares currently outstanding. According to the last transparency notification received by Mithra, Meusinvest previously held 15.47% of the 34,967,579 shares outstanding.

The detailed transparency notifications are available on the Investors website of Mithra (investors.mithra.com). An updated overview of the Mithra's large shareholdings will be included in the corporate governance charter of Mithra, which will be made available on its website.

**********

For more information, please contact:

Investor Relations

Sofie Van Gijsel, IRO & VP of Strategy +32 485 19 14 15 investorrelations@mithra.com

About Mithra

Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta®- are built on Mithra's unique natural estrogen platform, E4 (Estetrol). Mithra also develops, manufactures and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO.

{1}------------------------------------------------

Mithra was founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forwardlooking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com